Vicore held its Annual General Meeting on May 11, 2023 where Dr Elisabeth Björk and Dr Michael Buschle were elected to the Board of Directors, effective immediately.

Dr Elisabeth Björk is SVP, Late-Stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D at AstraZeneca, where she oversees clinical development from phase I-IV, large outcomes programs, major global filings and regulatory interactions, as well as global commercial strategy and implementation across regions and therapy areas. Prior to joining AstraZeneca in 2002, Dr Björk spent over 15 years in clinical practice and academic research. She also has experience serving as a director on the boards of small and mid-size international life science companies. Dr Björk is board certified in internal medicine and holds a PhD in endocrinology.

Dr Michael Buschle holds a PhD from University of London and has more than 25 years’ experience in basic research as well as from biotech and pharma R&D. Dr Buschle has held C-level positions at mid-size Pharma and biotech companies. Among others, Dr Buschle was a co-founder of vaccine company Intercell AG (merged with Vivalis to create Valneva in 2012) and President Biologics and Chief Scientific Officer at Glenmark Pharmaceuticals.

Dr Elisabeth Björk, Board Member of Vicore commented: “I look forward to contributing my experience in drug development through advising on clinical trials and successful launches. Vicore’s ATRAG biology is intriguing and the recent interim results with C21 in the IPF trial are very promising.”

Dr Michael Buschle, Board Member of Vicore said: “I find the Company portfolio and the underlying biology of ATRAGS highly interesting. There is potential that Vicore’s molecules may be effective in IPF and possibly also other diseases.”

Jacob Gunterberg, Chairman of the Board commented: “We are very happy to welcome Elisabeth and Michael to the board of Vicore. Their extensive experience and expertise in R&D and drug development will contribute greatly to the continued growth and success of Vicore.”

For further information, please contact:
Carl-Johan Dalsgaard, CEO
Tel: +46 70 975 98 63
carl-johan.dalsgaard@vicorepharma.com

Optimum Strategic Communications
Hana Malik, Eleanor Cooper, Katie Flint
Tel: +44 20 3882 2119
vicore@optimumcomms.com

This information was submitted for publication on May 12 at 08:00 CET.

About Vicore Pharma Holding AB (publ)
Vicore is an innovative Swedish clinical-stage pharmaceutical company dedicated to creating life- changing treatments in diseases where the AT2 (angiotensin II type 2) receptor has a central role in stopping and reversing disease pathology. The company is establishing a portfolio in rare lung diseases including idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH). C21 is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG). Almee™ (an investigational medical device in clinical development) is a digital therapeutic (DTx) based on cognitive behavioral therapy (CBT) created to address the psychological impact of living with pulmonary fibrosis. Inhaled IMID is a new formulation and delivery route of thalidomide targeting the severe cough associated with IPF. With our unique expertise in the ATRAG biology we fuel our pipeline with several new assets with long patent life for a variety of diseases, some of which could be partnered while others can be taken to the market by Vicore.
The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.